Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

BACKGROUND: Gemcitabine (GEM) plus nab‐paclitaxel (NabP) (GEM 1000 mg/m(2) IV over 30 minutes + NabP 125 mg/m(2) IV given days 1, 8, and 15 every 28 days) is one of the two standard of care combination therapies for metastatic pancreatic ductal adenocarcinoma (PDAC). Our cancer center has utilized G...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Rogers, Jane E., Mizrahi, Jonathan D., Xiao, Lianchun, Mohindroo, Chirayu, Shroff, Rachna T., Wolff, Robert, Varadhachary, Gauri R., Javle, Milind M., Overman, Michael, Fogelman, David R., Raghav, Kanwal P. S., Pant, Shubham, McAllister, Florencia
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Clinical Cancer Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7402810/
https://ncbi.nlm.nih.gov/pubmed/32519420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3229
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items